Lifevantage Corp (LFVN) stock
LFVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 20/3044% below fair value
$4.78+0.01 (+0.21%)
Close on Nov 17, 2026Market cap $59.88MP/E 11.9Yield 3.87%
Lifevantage pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Lifevantage's pe ratio was 11.8× on Nov 11, 2026, against 8.9× a year earlier. Over the last 5 years it ranged from 5.3× to 100.0×, with a median of 16.8×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 11.8× | +3.8 |
| 2025 | Dec 31, 2025 | 8.0× | −46.8 |
| 2024 | Dec 31, 2024 | 54.8× | +26.2 |
| 2023 | Dec 29, 2023 | 28.6× | −64.4 |
| 2022 | Dec 30, 2022 | 93.0× | +86.6 |
| 2021 | Dec 31, 2021 | 6.4× | −4.6 |
| 2020 | Dec 31, 2020 | 11.1× | −16.8 |
| 2019 | Dec 31, 2019 | 27.9× | −4.3 |
| 2018 | Dec 31, 2018 | 32.2× | −20.7 |
| 2017 | Dec 29, 2017 | 52.9× | +33.9 |
| 2016 | Dec 30, 2016 | 19.0× | −20.7 |
| 2015 | Dec 31, 2015 | 39.7× | +28.4 |
| 2014 | Dec 31, 2014 | 11.2× | −16.3 |
| 2013 | Dec 31, 2013 | 27.5× | −3.8 |
| 2012 | Dec 31, 2012 | 31.3× | – |
See a number that looks wrong?